Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer

Inclusion Criteria: Locally advanced carcinoma of the pancreas Arterial invasion or encasement Invasion/encasement of the portomesenteric veins Patients who have been previously denied operation Obstructive jaundice must be drained with a polyethylene biliary stent or surgical bypass prior to beginning treatment. White blood cell count > 3500 per ml and platelet count > 100,000 per ml Serum creatinine ≤ 1.5 mg/dl Bilirubin ≤ 1.5 ECOG performance status < 2 Exclusion Criteria: Prior chemotherapy, radiotherapy, or investigational agents for pancreatic cancer Evidence of distant metastasis or malignant lymphadenopathy Concurrent malignancies History of allergic reactions to celecoxib or to sulfa drugs No non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, magnesium or aluminum containing antacids, fluconazole or lithium may be administered within 5 days of study entry, during the study and for the 30 days following the completion of all study treatments. Pregnant women and lactating women Uncontrolled or serious intercurrent illness HIV-positive patients receiving combination antiretroviral therapy